OsoBio is installing a new oxygen–reduction system on all of its filling lines, significantly expanding its capacity to manufacture oxygen–sensitive parenterals.
The new oxygen–reduction system is flexible, allowing OsoBio to apply it to any combination of vial and stopper, and results in 2 to 5 percent residual oxygen.
“Oxygen represents a huge threat to the safety and efficacy of injectable drugs, especially those involving proteins,” said Mike Marek, technical project manager at OsoBio. “While OsoBio has always been able to manufacture oxygen–sensitive parenterals, this recent facility improvement expands our production capacity and allows us to accomplish the task more quickly and easily.”
OsoBio worked with Bosch to tailor the oxygen–reduction system for its facility. Installation of the new system will be completed by September.